Jorge Ivan Castillo-Quan, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Longevity | 6 | 2020 | 1031 | 1.330 |
Why?
|
| Lithium | 2 | 2019 | 617 | 1.040 |
Why?
|
| Glycogen Synthase Kinase 3 | 3 | 2019 | 443 | 0.690 |
Why?
|
| Pyrimidinones | 1 | 2019 | 373 | 0.620 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2017 | 336 | 0.610 |
Why?
|
| Aging | 5 | 2020 | 8352 | 0.530 |
Why?
|
| Pyridones | 1 | 2019 | 692 | 0.520 |
Why?
|
| Sirolimus | 2 | 2019 | 1560 | 0.520 |
Why?
|
| Hydrocortisone | 4 | 2010 | 1734 | 0.470 |
Why?
|
| Drosophila | 2 | 2019 | 1459 | 0.460 |
Why?
|
| Nutrigenomics | 2 | 2009 | 24 | 0.450 |
Why?
|
| Drosophila melanogaster | 4 | 2020 | 1751 | 0.420 |
Why?
|
| Trans-Activators | 2 | 2012 | 3051 | 0.410 |
Why?
|
| Caenorhabditis elegans | 2 | 2017 | 1408 | 0.410 |
Why?
|
| Metformin | 1 | 2016 | 806 | 0.380 |
Why?
|
| Adipose Tissue, White | 1 | 2012 | 355 | 0.360 |
Why?
|
| Geriatrics | 1 | 2013 | 377 | 0.360 |
Why?
|
| Insulin | 6 | 2017 | 6654 | 0.350 |
Why?
|
| Drosophila Proteins | 5 | 2020 | 1748 | 0.340 |
Why?
|
| Fibronectins | 1 | 2012 | 720 | 0.340 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2009 | 280 | 0.320 |
Why?
|
| Cushing Syndrome | 1 | 2008 | 241 | 0.290 |
Why?
|
| Depressive Disorder | 2 | 2010 | 3805 | 0.290 |
Why?
|
| Adipose Tissue, Brown | 1 | 2012 | 809 | 0.280 |
Why?
|
| Nerve Growth Factors | 1 | 2009 | 587 | 0.280 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 484 | 0.280 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2008 | 333 | 0.260 |
Why?
|
| Hyperinsulinism | 1 | 2007 | 414 | 0.250 |
Why?
|
| Diabetes Mellitus | 2 | 2012 | 5444 | 0.240 |
Why?
|
| Diabetes Complications | 1 | 2010 | 1395 | 0.230 |
Why?
|
| Autophagy | 3 | 2020 | 1311 | 0.210 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 993 | 0.210 |
Why?
|
| Alzheimer Disease | 3 | 2017 | 7261 | 0.210 |
Why?
|
| Repressor Proteins | 1 | 2011 | 3064 | 0.190 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 4355 | 0.160 |
Why?
|
| Parkinson Disease | 1 | 2011 | 2680 | 0.160 |
Why?
|
| Neuroaxonal Dystrophies | 1 | 2016 | 20 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2007 | 1648 | 0.150 |
Why?
|
| Xenobiotics | 1 | 2016 | 76 | 0.140 |
Why?
|
| Gaucher Disease | 1 | 2016 | 113 | 0.140 |
Why?
|
| Glucosylceramidase | 1 | 2016 | 129 | 0.140 |
Why?
|
| Group X Phospholipases A2 | 1 | 2015 | 1 | 0.140 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2015 | 11 | 0.140 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2016 | 450 | 0.140 |
Why?
|
| United Nations | 1 | 2015 | 158 | 0.130 |
Why?
|
| Mitochondria | 2 | 2020 | 3614 | 0.130 |
Why?
|
| Animals | 13 | 2020 | 169277 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2019 | 1929 | 0.130 |
Why?
|
| Lipid Peroxidation | 1 | 2015 | 312 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3891 | 0.130 |
Why?
|
| Caloric Restriction | 1 | 2016 | 344 | 0.120 |
Why?
|
| Lysosomes | 1 | 2016 | 893 | 0.110 |
Why?
|
| Biogenic Monoamines | 1 | 2010 | 53 | 0.100 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2017 | 857 | 0.100 |
Why?
|
| Neuroglia | 1 | 2016 | 919 | 0.100 |
Why?
|
| Dietary Carbohydrates | 1 | 2016 | 913 | 0.100 |
Why?
|
| Obesity | 1 | 2012 | 12267 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2017 | 2030 | 0.090 |
Why?
|
| Models, Biological | 3 | 2017 | 9815 | 0.090 |
Why?
|
| Dietetics | 1 | 2008 | 36 | 0.090 |
Why?
|
| Physical Conditioning, Animal | 1 | 2012 | 362 | 0.090 |
Why?
|
| Models, Animal | 1 | 2015 | 2198 | 0.080 |
Why?
|
| Stress, Physiological | 1 | 2016 | 1425 | 0.080 |
Why?
|
| Depression | 1 | 2007 | 7261 | 0.080 |
Why?
|
| Pituitary-Adrenal System | 1 | 2010 | 510 | 0.080 |
Why?
|
| Antioxidants | 1 | 2015 | 1672 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 2096 | 0.080 |
Why?
|
| Signal Transduction | 5 | 2020 | 23721 | 0.080 |
Why?
|
| Mexico | 1 | 2009 | 683 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2007 | 11099 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 1991 | 0.080 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2010 | 661 | 0.070 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2010 | 597 | 0.070 |
Why?
|
| Receptor, Insulin | 2 | 2020 | 868 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2015 | 3124 | 0.060 |
Why?
|
| Diabetic Neuropathies | 1 | 2007 | 416 | 0.060 |
Why?
|
| Humans | 14 | 2019 | 715636 | 0.060 |
Why?
|
| Gene Knockout Techniques | 2 | 2016 | 807 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2016 | 10513 | 0.060 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 649 | 0.050 |
Why?
|
| Diabetic Angiopathies | 1 | 2007 | 847 | 0.050 |
Why?
|
| Animals, Genetically Modified | 2 | 2017 | 1578 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 7883 | 0.050 |
Why?
|
| Genes, Mitochondrial | 1 | 2020 | 63 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 18185 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9498 | 0.050 |
Why?
|
| Diabetic Nephropathies | 1 | 2007 | 1034 | 0.050 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2020 | 586 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2017 | 4889 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2010 | 2826 | 0.040 |
Why?
|
| Thiadiazoles | 1 | 2017 | 55 | 0.040 |
Why?
|
| Oleanolic Acid | 1 | 2017 | 48 | 0.040 |
Why?
|
| Lithium Chloride | 1 | 2017 | 88 | 0.040 |
Why?
|
| Quality of Life | 1 | 2015 | 11719 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 314 | 0.030 |
Why?
|
| Female | 4 | 2019 | 377052 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2012 | 11955 | 0.030 |
Why?
|
| Rats | 1 | 2009 | 24802 | 0.030 |
Why?
|
| Triazoles | 1 | 2017 | 914 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 2032 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2008 | 12546 | 0.020 |
Why?
|
| Mice | 2 | 2017 | 80320 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2017 | 5371 | 0.020 |
Why?
|
| Neoplasms | 1 | 2016 | 20514 | 0.020 |
Why?
|
| Axons | 1 | 2016 | 1729 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 2222 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 2807 | 0.020 |
Why?
|
| Hypertension | 1 | 2007 | 8270 | 0.020 |
Why?
|
| Gene Expression | 1 | 2020 | 7950 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 162383 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2015 | 950 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 17399 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 214618 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2015 | 4228 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 9559 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 2017 | 3211 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2017 | 5109 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 12299 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 25191 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 70927 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2017 | 19905 | 0.010 |
Why?
|
| Cell Line | 1 | 2015 | 16574 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 16729 | 0.010 |
Why?
|
| Male | 1 | 2016 | 350156 | 0.010 |
Why?
|
| Neurons | 1 | 2017 | 9377 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 9028 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 29270 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 27366 | 0.000 |
Why?
|